Dung-Fang Lee

Dr. Lee received his Bachelor degree in Chemical Engineering and Master degree in Radiation Biology from National Tsing Hua University in Taiwan and PhD degree in Cancer Biology from the University Of Texas Graduate School Of Biomedical Sciences at Houston. In 2016 after completing the post-doctoral training in the Black Family Stem Cell Institute at Icahn School of Medicine at Mount Sinai, Dr. Lee joined the Department of Integrative Biology and Pharmacology, and the Center for Stem Cell and Regenerative Medicine at the University of Texas Health Science Center at Houston as an Assistant Professor. Dr. Lee is the first person applying iPSC disease model to study familial cancer syndrome. Currently, Dr. Lee is the CPRIT scholar in Cancer Research.

The Lee laboratory is dedicated to understand cancer pathological mechanisms by using patient-specific iPSCs and/or engineered ESCs. The Lee laboratory has established the first human Li-Fraumeni syndrome (LFS) disease model by using LFS patient-specific iPSCs to delineate the pathological mechanisms caused by mutant p53 in osteosarcoma. The Lee laboratory continues to apply TALENs and CRISPR/Cas9 genome editing tools to create variant p53 mutations in pluripotent stem cells (PSCs; e.g., iPSCs and ESCs) in order to explore the role of mutant p53 in osteosarcomagenesis. The Lee laboratory also works on modeling familial cancer syndromes with osteosarcoma predisposition by PSCs. Currently, the Lee laboratory applies whole genome sequencing, screening approaches and systems-level analyses to explore early genomic alterations and to understand dynamic alterations of the genomic landscape of LFS-associated osteosarcoma.

Dr. Lee’s research has been well recognized and published in journals as Cell, Cell Stem Cell, Molecular Cell, Cancer Cell, Cell Reports, Nature, Nature Cell Biology, Nature Protocols, Journal of Clinical Investigation, Trends in Cancer, and Trends in Biochemical Sciences.

Editorial Board

In Press

Volume 2, Issue 6

Current Issue

Volume 2, Issue 5

Archive

Submit Manuscript

CRR welcomes direct submissions from authors: Attach your word file with e-mail and send it to submissions@oatext.com alternatively to editor.crr@oatext.com

Publication Charges

Cancer Reports and Reviews is an Open Access journal and we do not charge the end user when accessing a manuscript or any article. This allows the scientific community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License". In line with other open access journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.

The publication charges for Cancer Reports and Reviews are GBP 1490.

Frequently Asked Questions (FAQs)

Why are your charges set at these levels?

All articles published in OA Text are open access. Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in OA Text Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles and submitting the articles in electronic citation database like CrossRef.

Our financial goals are to:

• Recover capitalization costs;
• Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development;
• Bend the publication-charge cost downward over time.

Who will pay the APC?

Corresponding author or Co-authors has to make the payment on acceptance of the article.

When should I pay?

Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior to submission.

*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.

How do I pay?

Authors or institutions can make payments by two modes as per their convenience.

1. Wire/Bank transfer
2. Card payment

Note: No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction charges may be levied on the author.

Can I be eligible for wavier on APC?

The waiver request will be considered on a case-by-case basis, and will be provided accordingly.

*The Waiver requests must be made during the submission process and will not be accepted after  processing of the manuscript.

Do I have to pay if my manuscript is rejected?

No, Article processing charges will not be applicable for articles rejected by the Editorial office.

Withdrawal Charges

Are reprints of my article included in the article processing charges (APCs)?

No, Article processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.

Special Issues

• Breast Cancer

  Handling Editor:
  Adrian Pablo Hunis
  Board Certified in Medical Oncology
  Assistant Professor of Internal Medicine
  School of Medicine, University of Buenos Aires, Argentina
  Director, Specialist in Oncology, School of Medicine
  University of Buenos Aires (UBA), Argentina.
  Head Professor of Oncology, Maimonides University, Argentina

  Description/Purpose of the Special Issue and the current relevance:

  Few diseases have been targeted in the last 20 years of both development and worry as cancer patients, obviously to the extent that other disorders are cured or chronic, cancer in general and BREAST CANCER in particular, has been an issue where medical advances have been very important, reaching 90% of the patients in the early stages and achieving long survivors in patients with disseminated disease.

  New diiagnostic methods, new tumor markers, the contribution of molecular biology and the development of new and better therapies, have contributed to the fact that this disease, today is a model of cancer curable in the initial stages and a chronic disease and with long survival, In patients with metastasis.

  This special issue of Breast Cancer, from the Journal of Cancer Reports and Reviews, with the help of leading specialists, will try to bring to light some controversial aspects of this important chapter of human oncology, a real public health problem for the Western world.

  Topic includes but not limited to:

  Current state of molecular biology in breast cancer.
  Liquid biopsy and breast cancer.
  Genomic tests as predictors of treatment and prognosis.
  Advances in hormone therapy in breast cancer.
  Triple negative breast cancer, clinical and therapeutic update.
  Target therapies and immunotherapy, role in breast cancer.
  New radiotherapy treatments techniques.
  

  Tentative deadlines for submission: October, 30, 2018
  Tentative deadline for the issue release:  November, 30, 2018

  ​Submit manuscript to: editor.crr@oatext.com